CN107356765B - A kind of immunoglobulin E detection kit and detection method - Google Patents
A kind of immunoglobulin E detection kit and detection method Download PDFInfo
- Publication number
- CN107356765B CN107356765B CN201710681037.9A CN201710681037A CN107356765B CN 107356765 B CN107356765 B CN 107356765B CN 201710681037 A CN201710681037 A CN 201710681037A CN 107356765 B CN107356765 B CN 107356765B
- Authority
- CN
- China
- Prior art keywords
- reagent
- buffer solution
- immunoglobulin
- polyethylene glycol
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 82
- 102000018358 immunoglobulin Human genes 0.000 title claims description 82
- 238000001514 detection method Methods 0.000 title claims description 53
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 83
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract description 17
- 239000001639 calcium acetate Substances 0.000 claims abstract description 17
- 235000011092 calcium acetate Nutrition 0.000 claims abstract description 17
- 229960005147 calcium acetate Drugs 0.000 claims abstract description 17
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 46
- 239000007853 buffer solution Substances 0.000 claims description 38
- 239000002202 Polyethylene glycol Substances 0.000 claims description 37
- 229920001223 polyethylene glycol Polymers 0.000 claims description 37
- -1 ethylphenyl Chemical group 0.000 claims description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 23
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 239000003755 preservative agent Substances 0.000 claims description 22
- 230000002335 preservative effect Effects 0.000 claims description 22
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000007983 Tris buffer Substances 0.000 claims description 14
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- 238000002835 absorbance Methods 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007993 MOPS buffer Substances 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008351 acetate buffer Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 4
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 4
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960003742 phenol Drugs 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 3
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 abstract 2
- 238000003556 assay Methods 0.000 description 17
- 238000005259 measurement Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides a kind of Immunoturbidimetric kit, it includes reagent R1 and reagent R2, wherein includes Nonidet P40 in reagent R1, includes Nonidet P40, magnesium salts, calcium acetate and antibody in reagent R2.Kit antibody performance of the invention is good, reproducible, reagent testing result is accurate, can satisfy requirement.
Description
Technical Field
The invention relates to the field of medical immunization in-vitro diagnosis, and particularly relates to an immunoglobulin E detection kit and a detection method.
Background
Turbidimetry is widely used in clinical testing. Immunoturbidimetry is now the most commonly used.
Most of the early immunoassay techniques analyze the presence or absence and content of specific proteins in a sample to be detected by observing the formation of precipitates, agglutination and hemolysis and measuring light scattering caused by aggregates, such as immunodiffusion, immunoelectrophoresis, direct and brief hemagglutination, passive hemagglutination, complement fixation experiments, etc., and these detection methods have the advantages of low cost, easy judgment of results, and easy technical mastery, and can be widely used for detecting various types of clinical samples. However, the above-mentioned methods tend to be eliminated due to their cumbersome operation, time-consuming and poor sensitivity and accuracy.
Immunoturbidimetry overcomes the above disadvantages and allows the development of automated instruments with precise quantitation in combination with clinical requirements. Therefore, for immunological detection, the immunoturbidimetry has the specificity of combining immunological antigen and antibody, has the characteristic of biochemical reaction, can detect a trace amount of substance to be detected in body fluid, particularly blood, on an automatic biochemical instrument, and is a practical clinical test technology with application prospect.
Immunoturbidimetry (Turbidimetric inhibition assay) is an antigen-antibody binding kinetic assay. The basic principle is as follows: when the antigen and antibody react in a special dilution system and in a suitable ratio (generally, an excess amount of antibody is specified), the formed soluble immune complex precipitates from the liquid phase under the action of the aggregation promoter in the dilution system to form microparticles, and turbidity appears in the reaction solution. When the antibody concentration is fixed, the amount of the immunocomplex formed increases with the increase in the amount of the antigen in the sample, and the turbidity of the reaction solution also increases. The content of the antigen in the sample can be calculated by measuring the turbidity of the reaction solution and comparing with a series of standard products.
Various detection instruments developed and developed based on the basic principle of immunoturbidimetry have been widely used in many aspects of clinical examination, which is the basic working principle of optical methods and immunological methods of blood coagulators; the method is a determination principle of apolipoprotein, hapten and other proteins in full-automatic biochemical determination; meanwhile, the method can also be applied to microorganism detection. By accurately quantifying a variety of substances, there is great clinical significance in the diagnosis, treatment and prognosis evaluation of many diseases.
The clinical commonly used immunoturbidimetry can directly analyze samples in batches on a full-automatic biochemical analyzer due to small sample consumption, and is simple to operate, but the currently established reagents and methods have some defects and shortcomings, which are mainly shown in that:
the antibody is easy to generate flocculent or flaky precipitation in the preservation process, so that the performance of the antibody is poor, the repeatability is poor, and the Coefficient of Variation (CV) is increased, the detection result of the reagent is inaccurate, a filtering step is added, the operation is complex, the antibody can be removed by filtering, the detection effect is influenced, a certain influence is caused on a patient, and the use requirement cannot be met.
Disclosure of Invention
In order to solve the problems, the invention discloses an immunoglobulin E detection kit and a detection method, and the reagent has the advantages of good stability, good uniformity, good detection result accuracy, convenient operation and convenient popularization and application.
In order to achieve the purpose, the invention provides the following technical scheme:
the invention provides an immunoglobulin E detection kit, which comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises 0.9-50g/L of ethyl phenyl polyethylene glycol, and the reagent R2 comprises 0.9-50g/L of ethyl phenyl polyethylene glycol, 0.01-15g/L of magnesium salt, 0.01-20.5g/L of calcium acetate and 10-1000mg/L of antibody.
An immunoglobulin E detection kit, wherein the ethyl phenyl polyethylene glycol in the reagent R1 is 4.5-42g/L, preferably 33 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 5-42g/L, preferably 29 g/L.
An immunoglobulin E detection kit, wherein the magnesium salt is 0.05-10g/L, preferably 7 g/L; the magnesium salt is preferably one or more of magnesium sulfate, magnesium chloride or magnesium acetate.
An immunoglobulin E detection kit, wherein the calcium acetate is 0.05-15g/L, preferably 12 g/L.
Wherein,
the reagent R1 also comprises buffer solution, inorganic salt, preservative and aggregate; preferably, the reagent R1 further comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L and aggregate 1-60 g/L.
The reagent R2 further comprises a buffer solution, an inorganic salt and a preservative, and preferably, the reagent R2 further comprises 20-100mmol/L of the buffer solution, 1-30g/L of the inorganic salt and 0.5-1g/L of the preservative.
An immunoglobulin E detection kit further comprises a calibrator, wherein the calibrator adopts multi-point calibration, and the calibrator comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.1-2g/L of preservative, 0.3-100g/L of glucan, 1-100g/L of trehalose, 1-100g/L of sucrose, 1-100g/L of bovine serum albumin and antigen.
An immunoglobulin E detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution 20-150mmol/L, an inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethylphenylpolyethylene glycol 0.9-50g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, an inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethylphenylpolyethylene glycol 0.9-50g/L, magnesium sulfate 0.01-15g/L and calcium acetate 0.01-20.5 g/L;
preferably, the first and second electrodes are formed of a metal,
the reagent R1 comprises a buffer solution 20-150mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethyl phenyl polyethylene glycol 4.5-42g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 5-42g/L, magnesium sulfate 0.05-10g/L and calcium acetate 0.05-15 g/L;
more preferably still, the first and second liquid crystal compositions are,
the reagent R1 comprises a buffer solution 20-150mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, polyethylene glycol 60001-60g/L and ethyl phenyl polyethylene glycol 33g/L, and the reagent R2 comprises a buffer solution 20-100mmol/L, inorganic salt 1-30g/L, a preservative 0.5-1g/L, an antibody 10-1000mg/L, ethyl phenyl polyethylene glycol 29g/L, magnesium sulfate 7g/L and calcium acetate 12 g/L.
An immunoglobulin E detection kit, which comprises a kit body,
preferably, the antibody is a goat anti-human, rabbit anti-human, horse anti-human, mouse anti-human or other animal anti-human antibody;
preferably, the buffer solution is one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution;
preferably, the inorganic salt is one or two of sodium chloride and potassium chloride;
preferably, the preservative is one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric thiosulfate;
preferably, the aggregate is one or more of polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000;
the invention also provides a detection method using the immunoglobulin E detection kit, which comprises the following steps:
(1) adding the reagent R1 into a sample to be detected, and uniformly mixing, wherein the volume ratio of the sample to be detected to the reagent R1 is (1-9): 300, incubating at 37 ℃, and reading the absorbance A1 at a certain wavelength;
(2) adding a reagent R2 into the mixed solution obtained in the step (1), and uniformly mixing, wherein the volume ratio of the reagent R2 to the reagent R1 is 1: (1-6) adding, incubating at 37 ℃, and reading the absorbance A2 at a certain wavelength;
(3) obtaining absorbance △ A, wherein the absorbance △ A is A2-A1;
(4) and (3) fitting a standard curve on a full-automatic biochemical analyzer by using the calibrator through a built-in curve fitting mode, and automatically calculating the content of the immunoglobulin E in the sample to be detected according to the absorbance.
The aggregate referred to in the present invention is a substance that promotes aggregation of antigen and antibody in a reaction.
The invention provides an immunoglobulin E detection kit and a detection method, and relates to the following raw material sources:
due to the adoption of the technical scheme, the invention has the beneficial effects that:
the immunoglobulin E detection kit and the detection method provided by the invention have the advantages of good reagent stability, good uniformity, stable storage of antibodies, no precipitation phenomenon, high antibody titer, good performance, no filtration step, convenience in operation, low cost, accurate detection result, good repeatability and wider universality.
Detailed description of the preferred embodiments
In order to make the technical solutions in the present application better understood, the present invention is further described below with reference to examples, and it is obvious that the described examples are only a part of the examples of the present application, but not all of the examples. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
Example 1 immunoglobulin E detection kit
Reagent R1:
| TRIS buffer | 20mmol/L |
| Chlorination ofSodium salt | 1g/L |
| Sodium azide | 0.5g/L |
| Polyethylene glycol 6000 | 1g/L |
| Ethyl phenyl polyethylene glycol | 0.9g/L |
Reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Anti-human immunoglobulin E antibody for sheep | 10mg/L |
| Ethyl phenyl polyethylene glycol | 0.9g/L |
| Magnesium sulfate | 0.01g/L |
| Calcium acetate | 0.01g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.2g/L sodium azide, 0.3g/L dextran, 1g/L trehalose, 2g/L sucrose, 2g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 120mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 2 immunoglobulin E detection kit
Reagent R1:
| phosphate buffer | 40mmol/L |
| Potassium chloride | 7g/L |
| Phenol and its preparation | 0.7g/L |
| Polyethylene glycol 6000 | 30g/L |
| Ethyl phenyl polyethylene glycol | 50g/L |
Reagent R2:
| phosphate buffer | 40mmol/L |
| Potassium chloride | 5g/L |
| Phenol and its preparation | 0.7g/L |
| Anti-human immunoglobulin E antibody for sheep | 50mg/L |
| Ethyl phenyl polyethylene glycol | 50g/L |
| Magnesium sulfate | 15g/L |
| Calcium acetate | 20.5g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (50mmol/L glycine buffer, 10g/L sodium chloride, 0.5g/L sodium azide, 20g/L dextran, 25g/L trehalose, 30g/L sucrose, 20g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 100mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 10mg/L, 30mg/L, 50mg/L, 70mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 3 immunoglobulin E detection kit
Reagent R1:
| acetate buffer solution | 80mmol/L |
| Potassium chloride | 20g/L |
| Sodium azide | 0.8g/L |
| Polyethylene glycol 6000 | 45g/L |
| Ethyl phenyl polyethylene glycol | 4.5g/L |
Reagent R2:
| acetate buffer solution | 80mmol/L |
| Potassium chloride | 20g/L |
| Sodium azide | 1g/L |
| Anti-human immunoglobulin E antibody for sheep | 300mg/L |
| Ethyl phenyl polyethylene glycol | 5g/L |
| Magnesium sulfate | 0.05g/L |
| Calcium acetate | 0.05g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (70mmol/L TRIS buffer, 25g/L sodium chloride, 1g/L sodium azide, 55g/L dextran, 50g/L trehalose, 60g/L sucrose, 75g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 200mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 2mg/L, 10mg/L, 40mg/L, 60mg/L, 80mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 4 immunoglobulin E detection kit
Reagent R1:
| MOPS buffer solution | 150mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Polyethylene glycol 6000 | 55g/L |
| Ethyl phenyl polyethylene glycol | 42g/L |
Reagent R2:
| MOPS buffer solution | 100mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Anti-human immunoglobulin E antibody for sheep | 600mg/L |
| Ethyl phenyl polyethylene glycol | 42g/L |
| Magnesium sulfate | 10g/L |
| Calcium acetate | 15g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (100mmol/L TRIS buffer, 15g/L sodium chloride, 1g/L sodium azide, 10g/L dextran, 100g/L trehalose, 95g/L sucrose, 100g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 160mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 20mg/L, 40mg/L, 70mg/L, 100mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.45 mu m, and storing at the temperature of 2-8 ℃.
Example 5 immunoglobulin E detection kit
Reagent R1:
| MOPS buffer solution | 150mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Polyethylene glycol 6000 | 55g/L |
| Ethyl phenyl polyethylene glycol | 33g/L |
Reagent R2:
| MOPS buffer solution | 100mmol/L |
| Sodium chloride | 30g/L |
| Sodium azide | 1g/L |
| Anti-human immunoglobulin E antibody for sheep | 100mg/L |
| Ethyl phenyl polyethylene glycol | 29g/L |
| Magnesium sulfate | 7g/L |
| Calcium acetate | 12g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (100mmol/L TRIS buffer, 30g/L sodium chloride, 0.5g/L sodium azide, 90g/L dextran, 100g/L trehalose, 100g/L sucrose, 100g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 120mg/L, stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 20mg/L, 50mg/L, 80mg/L, 100mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 6 immunoglobulin E detection kit
Reagent R1:
reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Anti-human immunoglobulin E antibody for sheep | 10mg/L |
| Ethyl phenyl polyethylene glycol | 0.9g/L |
| Magnesium sulfate | 0.01g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard dilutions (25mmol/L phosphate buffer, 2g/L sodium chloride, 0.2g/L sodium azide, 0.3g/L dextran, 1g/L trehalose, 3g/L sucrose, 3g/L bovine serum albumin), detected with commercially available control reagents and adjusted to 120mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 7 immunoglobulin E detection kit
Reagent R1:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Polyethylene glycol 6000 | 1g/L |
| Ethyl phenyl polyethylene glycol | 0.9g/L |
Reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Anti-human immunoglobulin E antibody for sheep | 10mg/L |
| Ethyl phenylPolyethylene glycol | 0.9g/L |
| Calcium acetate | 0.01g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.2g/L sodium azide, 0.3g/L dextran, 1g/L trehalose, 2g/L sucrose, 2g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 120mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Example 8 immunoglobulin E detection kit
Reagent R1:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Polyethylene glycol 6000 | 1g/L |
| Tween 20 | 0.9g/L |
Reagent R2:
| TRIS buffer | 20mmol/L |
| Sodium chloride | 1g/L |
| Sodium azide | 0.5g/L |
| Anti-human immunoglobulin E antibody for sheep | 10mg/L |
| Tween 20 | 0.9g/L |
Calibration products:
immunoglobulin E antigen was dissolved in standard diluent (20mmol/L phosphate buffer, 2g/L sodium chloride, 0.2g/L sodium azide, 0.3g/L dextran, 1g/L trehalose, 2g/L sucrose, 2g/L bovine serum albumin), detected with a commercially available control reagent, adjusted to 120mg/L, and stored at-20 ℃. Before use, the sample was taken out and diluted with a standard dilution to give immunoglobulin E standards (immunoglobulin E antigen concentration: 0mg/L, 10mg/L, 20mg/L, 50mg/L, 70mg/L) of different concentrations. Then filtering and sterilizing by using a filter membrane with the diameter of 0.65 mu m, and storing at the temperature of 2-8 ℃.
Comparing the detection results of different embodiments, wherein the CV value is STDEV (1-7)/mean value.
1. A sample with 40mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 1, and the assay results are shown in Table 1.
Table 1: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from table 1, the concentrations of immunoglobulin E measured in 1 month, 3 months, and 12 months in example 1 are all close to the true values, and the measured coefficient of variation (CV value) is less than 2%, which indicates that the kit of the present invention has good repeatability, stable performance, and accurate measurement.
2. A sample with an immunoglobulin E concentration of 1.0mg/L was prepared, and the assay was repeated 7 times using the kit of example 2, with the assay results shown in Table 2.
Table 2: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 2, the immunoglobulin E concentrations measured in 1 month, 3 months and 12 months in example 2 are all close to the actual values, and the measured variation coefficients are all less than 2%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
3. A sample with 25mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 3, and the assay results are shown in Table 3.
Table 3: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 3, the immunoglobulin E concentrations measured in 1 month, 3 months and 12 months in example 3 are all close to the true values, and the measured variation coefficients are all less than 1%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
4. A sample with an immunoglobulin E concentration of 70mg/L was prepared, and the assay was repeated 7 times using the kit of example 4, with the assay results shown in Table 4.
Table 4: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 4, the immunoglobulin E concentrations measured in 1 month, 3 months and 12 months in example 4 are all close to the actual values, and the measured variation coefficients are all less than 1%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
5. A sample with 25mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 5, and the assay results are shown in Table 5.
Table 5: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 5, the concentrations of immunoglobulin E measured in 1 month, 3 months and 12 months in example 5 are all true values, and the measured variation coefficients are all less than 0.05%, which indicates that the kit of the invention has good repeatability, stable performance and accurate measurement.
6. A sample with 40mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 6, and the assay results are shown in Table 6.
Table 6: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 6, the immunoglobulin E concentrations measured in 1 month, 3 months and 12 months in example 6 deviate from the true values, and the measured variation coefficients are all more than 4%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
7. A sample with 40mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 7, and the assay results are shown in Table 7.
Table 7: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 7, the immunoglobulin E concentrations measured in 1 month, 3 months and 12 months in example 7 all deviate from the true values, and the measured variation coefficients are all more than 4%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
8. A sample with 40mg/L of IgE was prepared, and the assay was repeated 7 times using the kit of example 8, and the assay results are shown in Table 8.
Table 8: the measurement result of the storage at 2-8 ℃ for 1 month, 3 months and 12 months
As can be seen from Table 8, the immunoglobulin E concentrations measured in example 8 at 1 month, 3 months and 12 months all deviate from the true values, and the measured variation coefficients are all greater than 5%, which indicates that the kit has poor repeatability, unstable performance and inaccurate measurement.
It is to be understood that the invention disclosed is not limited to the particular methodology, protocols, and materials described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (15)
1. An immunoglobulin E detection kit, characterized in that: the kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises 0.9-50g/L of ethylphenyl polyethylene glycol, and the reagent R2 comprises 0.9-50g/L of ethylphenyl polyethylene glycol, 0.01-15g/L of magnesium salt, 0.01-20.5g/L of calcium acetate and 10-600mg/L of antibody;
the reagent R1 also comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L and aggregate 1-60 g/L; the aggregate is a substance that promotes aggregation of antigen and antibody in the reaction;
the reagent R2 also comprises a buffer solution 20-100mmol/L, inorganic salt 1-30g/L and a preservative 0.5-1 g/L;
the antibody is preferably a sheep anti-human antibody, a rabbit anti-human antibody, a horse anti-human antibody, a mouse anti-human antibody or other animal anti-human antibody;
the inorganic salt in the reagent R1 and the reagent R2 is one or two of sodium chloride and potassium chloride.
2. The immunoglobulin E detection kit of claim 1, wherein: the ethyl phenyl polyethylene glycol in the reagent R1 is 4.5-42 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 5-42 g/L.
3. The immunoglobulin E detection kit of claim 2, wherein: the ethyl phenyl polyethylene glycol in the reagent R1 is 33 g/L; the ethyl phenyl polyethylene glycol in the reagent R2 is 29 g/L.
4. The immunoglobulin E detection kit of claim 1, wherein: the magnesium salt is 0.05-10 g/L.
5. The immunoglobulin E detection kit of claim 1, wherein: the magnesium salt is one or more of magnesium sulfate, magnesium chloride or magnesium acetate.
6. The immunoglobulin E detection kit of claim 4, wherein: the magnesium salt is 7 g/L.
7. The immunoglobulin E detection kit of claim 1, wherein: the calcium acetate is 0.05-15 g/L.
8. The immunoglobulin E detection kit of claim 7, wherein: the calcium acetate is 12 g/L.
9. The immunoglobulin E detection kit of any of claims 1-8, wherein: the kit comprises a calibrator, wherein the calibrator is calibrated by adopting multiple points, and the calibrator comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.1-1g/L of preservative, 0.3-100g/L of glucan, 1-100g/L of trehalose, 1-100g/L of sucrose, 1-100g/L of bovine serum albumin and an immunoglobulin E antigen; the inorganic salt is one or two of sodium chloride and potassium chloride.
10. An immunoglobulin E detection kit, characterized in that: the kit comprises a reagent R1 and a reagent R2,
the reagent R1 comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, polyethylene glycol 60001-60g/L, ethyl phenyl polyethylene glycol 4.5-42 g/L; the reagent R2 comprises buffer solution 20-100mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, antibody 10-600mg/L, ethyl phenyl polyethylene glycol 5-42g/L, magnesium sulfate 0.05-10g/L, calcium acetate 0.05-15 g/L;
the antibody is preferably a sheep anti-human antibody, a rabbit anti-human antibody, a horse anti-human antibody, a mouse anti-human antibody or other animal anti-human antibody;
the inorganic salt in the reagent R1 and the reagent R2 is one or two of sodium chloride and potassium chloride.
11. The immunoglobulin E detection kit of claim 10, wherein: the reagent R1 comprises buffer solution 20-150mmol/L, inorganic salt 1-30g/L, preservative 0.5-1g/L, polyethylene glycol 60001-60g/L, ethyl phenyl polyethylene glycol 33 g/L; the reagent R2 comprises 20-100mmol/L of buffer solution, 1-30g/L of inorganic salt, 0.5-1g/L of preservative, 10-600mg/L of antibody, 29g/L of ethyl phenyl polyethylene glycol, 7g/L of magnesium sulfate and 12g/L of calcium acetate;
the inorganic salt in the reagent R1 and the reagent R2 is one or two of sodium chloride and potassium chloride.
12. The immunoglobulin E detection kit of any of claims 1-8, wherein: the buffer solution is preferably one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution;
the preservative is preferably one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric thiosulfate;
the aggregate is preferably one or more of polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000.
13. The immunoglobulin E detection kit of claim 9, wherein:
the buffer solution is preferably one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution;
the preservative is preferably one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric sodium thiosulfate.
14. The immunoglobulin E detection kit of claim 10, wherein:
the buffer solution is preferably one or more of acetate buffer solution, ammonium chloride buffer solution, phosphate buffer solution, TRIS buffer solution, boric acid buffer solution, glycine buffer solution, CAPSO, MOPS or Hepes buffer solution;
the preservative is preferably one or more of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate or ethylmercuric sodium thiosulfate.
15. A method of detecting using the immunoglobulin E detection kit of any one of claims 1-8, comprising the steps of:
(1) adding the reagent R1 into a sample to be detected, and uniformly mixing, wherein the volume ratio of the sample to be detected to the reagent R1 is (1-9): 300, incubating at 37 ℃, and reading the absorbance A1 at a certain wavelength;
(2) adding a reagent R2 into the mixed solution obtained in the step (1), and uniformly mixing, wherein the volume ratio of the reagent R2 to the reagent R1 is 1: (1-6) adding, incubating at 37 ℃, and reading the absorbance A2 at a certain wavelength;
(3) obtaining absorbance △ A, wherein the absorbance △ A is A2-A1;
(4) and (3) fitting a standard curve on a full-automatic biochemical analyzer by using the calibrator through a built-in curve fitting mode, and automatically calculating the content of the immunoglobulin E in the sample to be detected according to the absorbance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710681037.9A CN107356765B (en) | 2017-08-10 | 2017-08-10 | A kind of immunoglobulin E detection kit and detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710681037.9A CN107356765B (en) | 2017-08-10 | 2017-08-10 | A kind of immunoglobulin E detection kit and detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107356765A CN107356765A (en) | 2017-11-17 |
| CN107356765B true CN107356765B (en) | 2018-11-23 |
Family
ID=60287860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710681037.9A Active CN107356765B (en) | 2017-08-10 | 2017-08-10 | A kind of immunoglobulin E detection kit and detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107356765B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102798725A (en) * | 2012-08-13 | 2012-11-28 | 沃克(天津)生物科技有限公司 | Diagnostic kit for determination of serum total IgE, preparation method and application method |
| CN105137062A (en) * | 2015-06-03 | 2015-12-09 | 章丘维他力医疗器械有限公司 | Immunoglobulin E immunoturbidimetry detection kit |
| CN105717300A (en) * | 2016-02-02 | 2016-06-29 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of immune globulin E and application of kit |
| JP2016200430A (en) * | 2015-04-08 | 2016-12-01 | 株式会社パートナーファーム | Tear collection and inspection tool |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170089893A1 (en) * | 2015-09-24 | 2017-03-30 | Globallergy, Llc | Chromatographic immune assay for the detection of allergic sensitivities |
-
2017
- 2017-08-10 CN CN201710681037.9A patent/CN107356765B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102798725A (en) * | 2012-08-13 | 2012-11-28 | 沃克(天津)生物科技有限公司 | Diagnostic kit for determination of serum total IgE, preparation method and application method |
| JP2016200430A (en) * | 2015-04-08 | 2016-12-01 | 株式会社パートナーファーム | Tear collection and inspection tool |
| CN105137062A (en) * | 2015-06-03 | 2015-12-09 | 章丘维他力医疗器械有限公司 | Immunoglobulin E immunoturbidimetry detection kit |
| CN105717300A (en) * | 2016-02-02 | 2016-06-29 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of immune globulin E and application of kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107356765A (en) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107462731B (en) | A kind of immune globulin A detection reagent box and detection method | |
| CN107402308A (en) | Immue quantitative detection reagent boxes of IL 6 and preparation method thereof | |
| CN105510604A (en) | Method for improving sensitivity and linearity of latex reagent | |
| CN102636653A (en) | Compounded latex particle-enveloped cystatin C detection kit | |
| CN107462729B (en) | A kind of Apolipoprotein A1 detection kit and detection method | |
| CN107478853B (en) | A kind of apolipoprotein B detection kit and detection method | |
| CN107490675B (en) | A kind of Immunoturbidimetric kit and detection method | |
| CN106324251A (en) | Preparation method of small-fragment BMG antibody and beta2-microglobulin detection kit | |
| CN107490696A (en) | A kind of Retinal-binding protein detection kit and detection method | |
| CN107478846B (en) | A kind of immunoglobulin G detection reagent box and detection method | |
| CN107449919B (en) | A kind of C reactive protein detection kit and detection method | |
| CN107462730B (en) | A kind of Complement C4 detection kit and detection method | |
| CN107478854B (en) | A kind of lipoprotein a detection kit and detection method | |
| CN107490676B (en) | A kind of Complement C_3 detection kit and detection method | |
| CN107490697B (en) | A kind of kit for testing prealbumin and detection method | |
| CN107422114B (en) | A kind of rheumatoid factor detection reagent box and detection method | |
| CN107356765B (en) | A kind of immunoglobulin E detection kit and detection method | |
| CN107356764A (en) | A kind of apolipoprotein E detection kit and detection method | |
| CN107478847B (en) | A kind of immune globulin M detection reagent box and detection method | |
| CN114137204B (en) | KL-6 determination kit and preparation and detection method thereof | |
| JP3513075B2 (en) | Immunoassay and reagent therefor | |
| CN102369441A (en) | Immunoassay method and reagent therefor | |
| WO2022065398A1 (en) | Ferritin measuring reagent | |
| CN109580931A (en) | A kind of α 1- microglobulin detection kit | |
| CN110392831A (en) | Method for modulating signal intensity in interaction assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |